IMMUNOTHERAPY IN ONCOLOGY
APAVAC FOR PETS
Thanks to the development of a kit of preparation of 8 mono doses of autologous vaccine, APAVAC is indicated in the treatment of the pets of cancers and treated by veterinarians in Europe and the USA.
The technology is robust and repeatable. In combination with chemotherapy, chemotherapy doses can be decreased with expected effects on adverse effects and cost.
APAVAC is protected by patents since 2005. In addition, research programs in veterinary medicine enable URODELIA to validate and complement its activities in immuno-oncology. Indeed, URODELIA uses its know-how to enable fundamental research to have a future in clinical medicine.